Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...
BTIG analysts began covering Arcturus Therapeutics (NASDAQ:ARCT) with a positive outlook, assigning a Buy rating and establishing a price target of $41.00. Currently trading at $16.49 with a market ...
Hosted on MSN1mon
Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short SellersIn this article, we are going to take a look at where Arcturus Therapeutics Holdings ... even if Wood hadn’t bought additional shares, her original holdings would currently be worth $62.7 ...
Arcturus Therapeutics Holdings Inc. (NASDAQ ... For more information see our T&C.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback